Nitric oxide (NO) has emerged as a novel regulator of several ovarian events, such as ovulation, steroidogenesis, and apoptotic cell death. The NO synthases (NOS) are a family of enzymes that catalyze the oxidation of L-arginine to NO and L-citrulline. The purpose of the present study was to localize NOS isoforms in the rat ovary and to examine their hormonal regulation. We conducted immunohistochemistry and Western blot analysis using isoform-specific antibodies against brain NOS, endothelial NOS (eNOS), and inducible NOS (iNOS). Immature rats were superovulated by injecting PMSG (10 IU sc) followed by an injection of human CG (hCG; 10 IU sc) 48 h later. Ovaries were obtained from control rats (no PMSG), 24 h and 48 h after PMSG treatment and 2 h, 8 h, 12 h, 20 h or 6 days and 10 days after hCG injection (n ϭ 3-5 rats/group). Rat ovaries were clearly devoid of brain NOS staining at any of the time points studied. In control ovaries, eNOS was detected in the theca cell layer, ovarian stroma, and on the surface of oocytes. During follicular development, eNOS staining was still expressed in the theca cell layer and was also present in mural granulosa cells. After ovulation, homogenous eNOS staining was observed within cells of the corpus luteum (CL). Western blots of ovarian homogenates demonstrated that during PMSG-induced follicle growth, eNOS levels increased by 2.5-fold relative to control rats (P Ͻ 0.05). eNOS levels were further increased 12 h and 20 h after hCG injection (5-fold and 7-fold, respectively, relative to control; P Ͻ 0.05). The greatest amount of eNOS was observed in ovaries 10 days after hCG injection (15-fold relative to control; P Ͻ 0.05). We also detected expression of iNOS in the ovary, but the pattern and cell-specific staining differed from that observed for eNOS. In immature ovaries and during follicular development, iNOS staining was found within the theca cell layer and stroma. After ovulation, iNOS staining was present only in the external layers of the developing CL, but in the degenerating CL (10 days post-hCG), strong staining in nonparenchymal cells was observed within the entire CL. Western blots showed no changes in levels of ovarian iNOS protein during follicular development, but a significant increase (6-fold relative to control; P Ͻ 0.05) was observed after an ovulatory dose of hCG. The highest level of iNOS was observed in ovaries 10 days after hCG injection (10-fold relative to control; P Ͻ 0.05). Our data demonstrate that ovarian eNOS and iNOS show distinct cell-specific expression patterns and are differentially regulated during follicular and luteal development. (Endocrinology 138: 460 -468, 1997) N ITRIC OXIDE (NO) is now acknowledged as an important product of mammalian cells with critical functions in the regulation of blood pressure, neurotransmission, and host defense (1, 2). It is synthesized from arginine by NO synthase (NOS), which exists in multiple isoforms (1, 2). To date, three genes encoding NOSs with different biochemical characteristics have been isolated (3, 4). Two constitutively expressed isoforms were first identified in the brain and in the endothelium. These isoforms require calcium and calmodulin for activity and respond to stimuli by producing small quantities of NO (3, 5) . In contrast, an inducible NOS (iNOS) has been found in a variety of cells, including cytokine-stimulated cells of the immune system (4). The expression of this isoform is correlated with cytotoxic/cytostatic events and results in a sustained synthesis of NO over long periods (1, 2) . NO exerts many of its functions by reacting with metal-and thiol-containing proteins, which can result in both activation and inhibition of the target protein (6).
duced follicle growth, eNOS levels increased by 2.5-fold relative to control rats (P Ͻ 0.05). eNOS levels were further increased 12 h and 20 h after hCG injection (5-fold and 7-fold, respectively, relative to control; P Ͻ 0.05). The greatest amount of eNOS was observed in ovaries 10 days after hCG injection (15-fold relative to control; P Ͻ 0.05). We also detected expression of iNOS in the ovary, but the pattern and cell-specific staining differed from that observed for eNOS. In immature ovaries and during follicular development, iNOS staining was found within the theca cell layer and stroma. After ovulation, iNOS staining was present only in the external layers of the developing CL, but in the degenerating CL (10 days post-hCG), strong staining in nonparenchymal cells was observed within the entire CL. Western blots showed no changes in levels of ovarian iNOS protein during follicular development, but a significant increase (6-fold relative to control; P Ͻ 0.05) was observed after an ovulatory dose of hCG. The highest level of iNOS was observed in ovaries 10 days after hCG injection (10-fold relative to control; P Ͻ 0.05). Our data demonstrate that ovarian eNOS and iNOS show distinct cell-specific expression patterns and are differentially regulated during follicular and luteal development. (Endocrinology 138: 460 -468, 1997) N ITRIC OXIDE (NO) is now acknowledged as an important product of mammalian cells with critical functions in the regulation of blood pressure, neurotransmission, and host defense (1, 2) . It is synthesized from arginine by NO synthase (NOS), which exists in multiple isoforms (1, 2) . To date, three genes encoding NOSs with different biochemical characteristics have been isolated (3, 4) . Two constitutively expressed isoforms were first identified in the brain and in the endothelium. These isoforms require calcium and calmodulin for activity and respond to stimuli by producing small quantities of NO (3, 5) . In contrast, an inducible NOS (iNOS) has been found in a variety of cells, including cytokine-stimulated cells of the immune system (4) . The expression of this isoform is correlated with cytotoxic/cytostatic events and results in a sustained synthesis of NO over long periods (1, 2) . NO exerts many of its functions by reacting with metal-and thiol-containing proteins, which can result in both activation and inhibition of the target protein (6) .
NO is synthesized by rat and human ovarian cells and has been shown to influence steroidogenesis, ovulation rate, and ovarian apoptotic cell death (7) (8) (9) (10) (11) (12) . We have identified endothelial NOS (eNOS) and iNOS in rat luteinized ovaries and have shown that NO negatively regulates luteal estradiol synthesis in vitro (13) . NO also has been suggested to play a role in ovulation. Rodents treated with pharmacological inhibitors of NOS show a reduced ovulation rate relative to controls, and NO has been proposed to function in ovulatory inflammatory events (7, 9, 10, 12, 14) . However, NO also has been shown to lower follicular apoptotic cell death, which may independently influence ovulation rate (11) . Recently, the expression of the messenger RNAs (mRNAs) for eNOS and iNOS in the rat ovary have been shown to be regulated during follicular development (15) .
In the present study, we examined the expression of NOS proteins in the rat ovary during follicular development, ovulation, and pseudopregnancy. Using isoform-specific antisera, we localized eNOS and iNOS in the rat ovary. We found that both the constitutive endothelial and inducible isoforms of NOS show distinct cell-specific expression patterns and exhibit regulation by the hormonal signals that direct ovarian development.
Materials and Methods

Hormones, chemicals, and antibodies
PMSG was obtained from Calbiochem (La Jolla, CA) and human CG (hCG; Profasi) was purchased from Serono (Randolph, MA). Aprotinin, BSA (V fraction), bacterial lipopolysaccharide (LPS; 0111:B4), leupeptin, ␤-mercaptoethanol, paraformaldehyde, 30% hydrogen peroxide, Ponceau S, phenylmethylsulfonyl fluoride, soybean trypsin inhibitor, and Triton X-100 were obtained from Sigma Chemical Co. (St. Louis, MO). Dithithreitol and propidium iodide (PI) were obtained from Boehringer Mannheim (Indianapolis, IN). Tissue-Tek OCT Compound was purchased from Miles (Elkhart, IN) and 4 -20% SDS-PAGE gradient gels were obtained from Novex (San Diego, CA). Polyvinylidene difluoride membrane (Immobilon-P membrane) was from Millipore (Bedford, MA). The eNOS polyclonal rabbit antiserum was a gift from Monsanto/ G.D. Searle (St. Louis, MO) and was prepared using a peptide fragment corresponding to amino acids 1173-1192 of bovine eNOS (16) . The brain NOS (bNOS), eNOS, and iNOS monoclonal mouse antibodies and eNOS polyclonal rabbit antiserum were obtained from Transduction Laboratories (Lexington, KY). The iNOS polyclonal rabbit antiserum was purchased from Upstate Biotechnology Inc. (Lake Placid, NY). An antirabbit glyceraldehyde-3-phosphate dehydrogenase (GAPDH) monoclonal antibody was purchased from Chemicon International (Temecula, CA). Biotinylated goat antirabbit IgG (HϩL); biotinylated horse antimouse IgG (HϩL); fluorescein-isothiocyanate-avidin; avidin/biotin blocking kit; normal goat, horse, and rabbit sera; rabbit IgG; and Vectashield mounting medium were purchased from Vector Laboratories (Burlingame, CA). Control ascites fluid was purchased from ICN Biomedicals (Costa Mesa, CA). Horseradish peroxidase (HRP)-conjugated antimouse IgG, rainbow colored protein molecular mass markers, and an enhanced chemiluminescence (ECL) detection kit for Western blot analysis were obtained from Amersham (Arlington, Heights, IL). Cell lines CRL 1733 bovine pulmonary artery endothelial cells and RAW 264.7 mouse macrophages were obtained from American Type Culture Collection (Rockville, MD).
Animals and tissue preparation
Immature female Sprague-Dawley rats (24 days old) were obtained from SASCO (Omaha, NE). Animals were housed in a 25 C room with a 14-h light, 10-h dark cycle. The rats received rat chow and tap water ad libitum. Immature rats (25 days old) were given either an sc injection of saline (control) or 10 IU of PMSG. Forty eight hours later, the PMSGtreated rats were injected sc with 10 IU of hCG (27 days old). These treatments cause a large cohort of follicles to undergo sequentially follicular development, ovulation, luteinization, pseudopregnancy, and luteolysis (17, 18) . Pseudopregnancy lasts approximately 10 days, and physiologically mimics the first half of a rat gestation (17, 18) . The control group of rats were killed on days 25, 26, and 27 of age. Two treatment groups were killed 24 h and 48 h after PMSG treatment (on days 26 and 27 of age; follicular development). The remaining rats were killed 2 h, 8 h, 12 h, 20 h or 6 days and 10 days after hCG injection (ovulation followed by luteinization). Ovaries were removed and either immediately snap-frozen in liquid nitrogen or placed in Tissue-Tek OCT embedding compound and frozen in liquid nitrogen. Frozen specimens were stored at Ϫ80 C until sectioned for immunohistochemistry or used for Western blot analysis. Each group of rats consisted of 3-5 animals, and both ovaries from each rat were examined. All animals were killed with 100% CO 2 followed by cervical dislocation.
The animal protocol used was approved by the Washington University Medical School institutional committee on laboratory animal care and was conducted in accordance with the NIH guide for the care and use of laboratory animals.
Immunofluorescent staining
The immunostaining procedure was performed by a modified immunofluorescence technique (13, 19) . Cryosections (6 m in thickness) were cut at Ϫ17 C on a Reichert-Jung cryostat (Leica, Heilderberg, Germany) and mounted on microscopic slides coated with poly-l-lysine (Sigma Chemical Co.). After 30 min at 25 C, slides were fixed in Carnoy's solution (ethanol-chloroform-glacial acetic acid, 6:3:1, for bNOS and eNOS stainings) or in freshly prepared 1% paraformaldehyde solution (for iNOS staining) in PBS (0.01 m phosphate, 0.14 m NaCL; pH 7.4). After washing twice with distilled water for 5 min each time, slides were treated with 0.3% hydrogen peroxide in absolute methanol for 30 min to quench endogenous peroxidase activity. Then the slides were washed twice in distilled water and twice in PBS containing 0.3% Triton X-100. All subsequent incubations with immunochemicals were performed in a humidified chamber.
To reduce nonspecific binding, blocking buffer (PBS containing 5% normal horse serum for monoclonal antibody or PBS with 5% normal goat serum for polyclonal antisera) with avidin solution (blocking kit; 4 drops/ml of buffer) was applied to slides for 60 min at 25 C. Sections were incubated either with a bNOS monoclonal mouse antibody, eNOS, or iNOS polyclonal rabbit antisera, each diluted 1:100 in blocking buffer with biotin solution (blocking kit; 4 drops/ml of buffer) overnight at 4 C. After four washes with PBS, slides were incubated with biotinylated horse antimouse IgG (1:100 dilution in blocking buffer) or biotinylated goat antirabbit IgG (1:200 dilution in blocking buffer) for 90 min at 25 C. After washes in PBS, the final detection step was performed for 1 h at 25 C in the dark with fluorescein-isothiocyanate-avidin (1:20 dilution in PBS). After this incubation, the slides were washed four times in PBS and subsequently counterstained with PI (1:500 dilution in PBS) to visualize all cellular nuclei. After three washes in PBS, slides were mounted in Vectashield mounting medium.
For each primary antibody (bNOS, eNOS, and iNOS) the immunostaining procedure was conducted on several sections from each ovary. Several negative control sections per ovary were incubated with control ascites fluid in place of the monoclonal antibody, or normal rabbit serum or rabbit IgG in place of polyclonal antisera. An additional negative control was conducted for the eNOS polyclonal rabbit antiserum obtained from Monsanto/G.D. Searle (16) . To confirm that eNOS immunofluorescent localization was specific, a blocking assay was conducted in which the primary antiserum was preincubated with an excess of the antigen peptide (50 g/ml) for 4 h at 25 C. This preincubated antiserum solution was used for immunostaining as described above.
Incident light fluorescence was monitored with a Nikon light microscope equipped with a mercury lamp and a dual wavelength filter (Boyce Scientific, St. Louis, MO) to permit the simultaneous detection of green and red fluorescence. Ektachrome 400 film (Eastman Kodak, Rochester, NY) was used for photomicroscopy.
Western blot analysis for eNOS and iNOS
To quantitate changes in protein levels, Western blot analysis of ovarian homogenates was performed according to the procedure described by Olson et al. (13, 20) . Because rat ovaries did not show any positive immunostaining for bNOS at any of the time points examined (data not presented), Western blot analysis was performed only for eNOS and iNOS.
Briefly, frozen rat ovaries from control rats (no PMSG; 27 days old), from rats 48 h after PMSG treatment (27 days old), and 12 h, 20 h, and 10 days after hCG treatment, were placed in 300 l of ice-cold homogenization buffer (50 mm Tris-base, pH 7.4; 10 mm EDTA; 150 mm NaCl; and 0.1% Tween-20 with the addition of 5 g/ml aprotinin, 5 g/ml leupeptin, 0.1% ␤-mercaptoethanol, 0.1 mm phenylmethylsulfonyl fluoride, and 10 g/ml soybean trypsin inhibitor), homogenized on ice with a Micro Tissue Grinder (Kontes, Vineland, NJ) and centrifuged at 25,000 ϫ g for 30 min at 4 C. The protein content of the resulting supernatant was determined using BSA as the standard (21) . Equal amounts of protein (65 g) from homogenized ovaries were diluted in 6ϫ SDS sample buffer (0.125 m Tris-Cl, pH 6.8; 10% SDS; 30% glycerol; 9.3% dithithreitol; and 0.012% bromophenol blue dye) and heated at 95 C for 4 min. Protein fractions were loaded onto 4 -20% gradient SDS-PAGE gels and electrophoretically separated for 2 h at constant current (30 mA) (22) . Rainbow-colored protein molecular mass markers (14.3-200 kDa) were always run on each gel. Separated proteins were electrotransferred onto Immobilon-P membranes using a Mini Electrophoretic Transfer Cell (Bio-Rad Laboratories, Hercules, CA) at 4 C overnight at constant voltage (30 V) in a buffer containing 20% methanol, 25 mm Tris, 192 mm glycine, and 0.02% SDS. Then the membranes were washed in 0.05% Tween-20 in a solution of 137 mm NaCl and 20 mm Tris at pH 7.5 (T-TBS) and incubated in blocking buffer (5% milk powder in T-TBS) for 1 h at 25 C. The presence of eNOS or iNOS was confirmed by incubating the membranes in blocking buffer containing either eNOS or iNOS monoclonal antibody at a dilution of 1:2,500 and 1:1,000, respectively. After washing in T-TBS, immunoblots were incubated with a HRP-conjugated antimouse IgG (1:5,000 dilution for eNOS or 1:3,500 dilution for iNOS in blocking buffer) for 1 h at 25 C. Finally, the NOS isoforms were detected using the ECL detection kit. The relative levels of eNOS and iNOS in rat ovaries were quantified by densitometric scanning of the exposed films from Western blots (n ϭ 5 rats for eNOS and n ϭ 3 rats for iNOS in each treatment group) using Molecular Dynamics Image Quant Software on a Personal Densitometer (Molecular Dynamics, Sunnyville, CA).
Several cell lines and rat tissues were used as positive and negative control samples on eNOS and iNOS Western blots. Positive controls for eNOS included homogenates of bovine endothelial cells (23) and rat lung and uterus (collected 20 h after hCG injection) (24) . Samples that were expected to be negative for eNOS were homogenates of LPSactivated (10 g/ml for 10 h) RAW 264.7 macrophages and rat cerebellum (obtained 20 h after hCG injection) (23, 25) . Positive controls for iNOS included homogenates of LPS-activated RAW 264.7 macrophages (26), and liver and spleen homogenates from rats injected with LPS (2 mg/kg BW, ip for 6 h) (27, 28) . The homogenate from bovine endothelial cells was included as a negative control for iNOS (25) .
To verify equal protein loading, Immobilon-P membranes (before immunodetection of eNOS and iNOS) always were stained with Ponceau S and washed with distilled water. In addition, to determine the specificity of changes in eNOS and iNOS expression, Western blots for GAPDH were conducted according to the method described above. We expected the level of GAPDH, often considered a housekeeping protein, to remain constant during follicular and luteal development. Immobilon-P membranes that had been used for eNOS and iNOS immunodetections were stripped of bound antisera (n ϭ 2) and reprobed with a GAPDH monoclonal antibody at a dilution of 1:300. After washing in T-TBS, immunoblots were incubated with a HRP-conjugated antimouse IgG at the dilution of 1:2,500 and detected using the ECL detection kit.
Statistical analysis
One-way ANOVA was used to analyze the changes in eNOS and iNOS protein levels during follicular development, ovulation, and pseudopregnancy, followed by linear contrasts to determine significance between means (16). The relative expressions of eNOS and iNOS were calculated by dividing the protein levels in each treatment group by the protein level in the control group (no PMSG; 27-day-old rats). P Ͻ 0.05 was considered to be significant. Data were analyzed using the Number Cruncher Statistical System Software version 5.03 (NCSS, Oakland, CA) (29) .
Results
Immunofluorescent localization of eNOS in rat ovaries
The cell-specific expression of eNOS was examined during ovarian follicular development, ovulation, and pseudopregnancy using polyclonal rabbit antisera and immunofluorescence. Immature ovaries obtained from control rats on 25, 26, and 27 days of age (no PMSG) contained follicles in early antral stages with multiple layers of granulosa cells surrounding oocytes. Light yellow-green immunostaining indicated the presence of eNOS in the theca cell layer and stroma cells and on the surface of oocytes (Fig. 1A for an ovary from a 27-day-old rat). PI counterstaining identified all cell nuclei, as indicated by red fluorescence. No specific staining was found within the granulosa cell layer (Fig. 1A) . All three control groups showed the same pattern of ovarian eNOS staining. After stimulation of follicular development with PMSG for 24 h or 48 h (26-and 27-day-old rats, respectively), many large antral follicles with well-delineated, multiple granulosa and theca cell layers were present (Fig. 1B for  48 h; data not presented for 24 h). The cytoplasm of cells in the theca layer and scattered granulosa cells showed strong positive green immunofluorescent staining, suggesting that PMSG induced eNOS expression in these cells (Fig. 1B) . After injection of hCG (2 h, 8 h, and 12 h), follicles containing strong green immunofluorescence in both theca and granulosa cell layers remained, indicating the continued presence of eNOS protein (Fig. 1C for 12 h; data not presented for 2 h and 8 h). Within granulosa cells, a heterogenous pattern of staining was observed. Mural granulosa cells (located near the basal lamina) showed strong positive staining for eNOS, whereas antral granulosa cells (located near the follicle antrum) were negative (Fig. 1C ). This staining pattern shows that hCG administration resulted in expression of eNOS within specific granulosa cell subtypes. After ovulation and luteinization, 20 h post-hCG injection, immunoreactivity for eNOS was seen as punctate cytoplasmic staining in luteal parenchymal cells of the developing corpus luteum CL (Fig. 1D) . In well-established CL (6 days after hCG injection; data not presented) and in degenerating CL (10 days after hCG injection), intensely stained luteal parenchymal and nonparenchymal cells (e.g. endothelial, fibroblast) were observed, and the distribution of staining seemed uniform throughout the entire CL (Fig. 1E) . Control slides for each ovary were stained with normal rabbit serum or rabbit IgG instead of primary antiserum. An example of a control slide from an ovary obtained 48 h after PMSG injection is shown in Fig. 1F . No immunofluorescent staining is observed. All other negative control slides at each stage of ovarian development also were negative (data not presented). In addition, no apparent staining was observed when the primary eNOS antiserum was preincubated with an excess of the antigen peptide (data not presented).
These data demonstrate that rat ovarian eNOS expression is regulated during folliculogenesis. eNOS was localized to the theca cell layer and stroma cells and the surface of oocytes in control ovaries. During follicular development, increased staining was observed in both theca cell layer and granulosa cells. At ovulation, no further changes in expression of eNOS were detected, but enhanced eNOS staining was observed within the CL, both 6 and 10 days after hCG injection.
Western blot analysis of eNOS in rat ovaries
To quantitate the changes in eNOS expression during follicular development, ovulation, and pseudopregnancy, relative eNOS protein levels were determined by Western blot analysis (Fig. 2) . We observed a protein of approximately 135 kDa [the molecular mass of eNOS (23, 30 -33) ] in bovine endothelial cells (Fig. 2A, lane 1) , ovaries obtained from control rats (no PMSG; 27 days old) or 48 h after PMSG injection (27 days old) and 12 h, 20 h, and 10 days after hCG injection ( Fig. 2A, lanes 2-6) , and in rat uterus and lung ( Fig.  2A, lanes 11-12) . We did not detect eNOS in homogenates of LPS-activated RAW 264.7 macrophages (Fig. 2A, lane 10) or rat cerebellum (Fig. 2A, lane 13) . In addition, we failed to detect eNOS in ovarian homogenates when eNOS antibody was omitted ( Fig. 2A , lanes 7-9 are representative controls for lanes 4 -6, respectively).
Average changes in eNOS expression during follicular development, ovulation, and pseudopregnancy, quantitated using laser densitometry, are shown in Fig. 2B . During FIG. 1 . Immunofluorescent staining (yellow-green fluorescence) of eNOS in cryosections of rat ovaries during follicular development, ovulation, and pseudopregnancy. All sections were counterstained with PI (red fluorescence) to visualize cellular nuclei. A, Control rats (no PMSG; 27 days old) show positive staining in theca cell layer and stroma cells (arrows) and on the surface of oocytes. B, After stimulation with PMSG for 48 h (27-day-old rats), eNOS staining is present in both the theca cell layer (arrow) and in scattered granulosa cells. C, Large Graafian follicle 12 h after hCG injection shows intense eNOS staining in both the theca cell layer (arrow) and mural granulosa cells (arrow). D, Formation of the early CL was observed 20 h after hCG injection. Few luteal parenchymal cells express punctate eNOS staining (arrows). E, In the CL, 10 days after hCG injection, uniform distribution of eNOS staining is observed (arrows). Inset, eNOS is strongly stained in the cytoplasm of luteal parenchymal and nonparenchymal cells (magnified 255%). F, A negative control of ovarian section obtained 48 h after PMSG injection and incubated with normal rabbit serum, in place of primary antiserum, shows no green immunofluorescence. G, Granulosa cell layer; T, theca cell layer; O, oocyte. Bar ϭ 50 m.
PMSG-induced follicular growth, eNOS levels increased 2.5-fold relative to control ovaries (P Ͻ 0.05). eNOS levels were further increased 12 h and 20 h after hCG injection, compared with control ovaries (5-fold and 7-fold, respectively; P Ͻ 0.05). However, the greatest amount of eNOS was observed in ovaries 10 days after hCG injection, which contained 15-fold greater eNOS levels than control ovaries (P Ͻ 0.05).
There were no changes in expression of GAPDH during hormone-directed ovarian differentiation (Fig. 5) . These data indicate that equal amounts of protein were loaded and support the specificity of the eNOS response to gonadotropin treatment. These quantitative data are consistent with the changes in eNOS expression observed immunohistochemically and demonstrate that in the ovary, eNOS is not a constitutively expressed enzyme. Indeed, ovarian eNOS exhibits a distinct, hormone-regulated expression pattern during follicular development, ovulation, and pseudopregnancy in this rat model.
Immunofluorescent localization of iNOS in rat ovaries
We also examined the cellular location of iNOS within the rat ovary during follicular development using a polyclonal rabbit antiserum and immunofluorescence technique (Fig. 3) . In ovaries obtained from control rats (no PMSG; 25, 26, or 27 days old), we found iNOS expressed within the theca cell layer and stroma surrounding immature follicles ( Fig. 3A ; yellow-green fluorescence for an ovary from a 27-day-old rat). All three control groups showed the same pattern of ovarian iNOS staining. When follicular development was stimulated with PMSG for 24 h (data not presented) or 48 h (27-day-old rats), we saw a slight increase in iNOS within the theca cell layer and stroma (Fig. 3B) . In contrast to eNOS expression, we did not observe any staining within granulosa cells or on the surface of oocytes. Thus, the cellular expression pattern of iNOS and eNOS are distinct. Furthermore, unlike the eNOS isoform, iNOS is not induced during follicular development. After hCG injection (2 h, 8 h, and 12 h), strong positive immunofluorescent staining was observed within the theca cell layer of preovulatory and ovulatory follicles and the interstitial cells surrounding them (Fig. 3C for 12 h; data not presented for 2 h and 8 h). At 20 h after hCG injection (about 8 h after ovulation), iNOS immunoreactivity had decreased and was observed only in cells of external layers of the developing CL (Fig. 3D) . In degenerating CL (10 days after hCG injection; Fig. 3E ), iNOS positive staining was expressed in nonparenchymal cells within the CL. An example of a negative control section (ovary obtained 10 days post-hCG) incubated with normal rabbit serum, instead of iNOS antiserum, shows no immunofluorescent staining (Fig.  3F) . All other control slides at each stage of ovarian development also were negative (data not presented).
In summary, iNOS was found within the theca cell layer and stroma of immature ovaries and was markedly enhanced during the periovulatory period. The enhanced expression of iNOS also was observed in cells within the degenerating CL.
Western blot analysis for iNOS in rat ovaries
On the basis of immunostaining, levels of iNOS seemed to be hormonally regulated. We confirmed the presence of iNOS in the rat ovary using Western blot analysis with an iNOS-specific monoclonal antibody (Fig. 4) . We detected a protein migrating at approximately 130 kDa [the molecular mass of iNOS has been reported to vary between 130 -150 kDa (4, 25, (32) (33) (34) ] in homogenates of LPS-activated RAW 264.7 macrophages (Fig. 4A, lane 1) , ovarian homogenates from control rats (no PMSG; 27 days old) or 48 h after PMSG
FIG. 2. A, Representative
Western blot of eNOS protein in rat ovaries during follicular development, ovulation, and pseudopregnancy. Ovarian homogenates (65 g) were subjected to 4 -20% gradient SDS-PAGE followed by immunoprobing with a monoclonal eNOS antibody. In (A), lanes are as follows: 1 ϭ 8 g bovine endothelial (End.) cells; 2 ϭ ovary from control rats (no PMSG, 27 days old); 3 ϭ ovary 48 h after PMSG injection (27-day-old rats); 4 ϭ ovary 12 h after hCG injection; 5 ϭ ovary 20 h after hCG injection; 6 ϭ ovary 10 days after hCG injection; 7-9 ϭ represent negative controls to lanes 4 -6, respectively, when eNOS antibody was omitted; 10 ϭ 2 g LPS-activated RAW 264.7 macrophages (LPS/RAW cells); 11-13 ϭ 65 g of rat uterus, lung, and cerebellum, respectively. The positions of molecular mass markers are indicated; B, Quantitative analysis of ovarian eNOS expression after gonadotropin treatment. The immunoblot signals were quantitated by a densitometer, and the value for no PMSG (control) was arbitrarily set as 1. Data points represent the mean Ϯ SEM; n ϭ 5 rats/group. Means with different superscripts are significantly different (P Ͻ 0.05).
injection (27-day-old rats) and 12 h, 20 h, and 10 days after hCG injection (Fig. 4A, lanes 2-6) , and homogenates of liver and spleen from a LPS-injected rats (Fig. 4A, lanes 10 -11) . We did not detect iNOS protein in bovine endothelial cells (Fig.   4A, lane 9) . Ovarian homogenates also were negative when iNOS antibody was omitted (Fig. 4A , lanes 7 and 8 are representative controls for lanes 5 and 6, respectively). For ovaries from rats 12 h after hCG injection, a second band of FIG. 3 . Immunofluorescent staining (yellow-green fluorescence) of iNOS in cryosections of rat ovaries during follicular development, ovulation, and pseudopregnancy. All sections were counterstained with PI (red fluorescence) to visualize cellular nuclei. A, Control rats (no PMSG; 27 days old) show positive staining in theca cell layer and some stroma cells (arrows). B, After stimulation with PMSG for 48 h (27-day-old rats), iNOS staining is present in theca cell layer (arrow) and interstitial cells (arrow) and absent in granulosa cells. C, Large Graafian follicle, 12 h after hCG injection, shows intense iNOS staining in both the theca cell layer and interstitial cells (arrows). D, Formation of early CL was observed 20 h after hCG injection. iNOS staining is expressed in cells of external layers of CL (arrows). E, In the CL, 10 days after hCG injection, intense iNOS staining in the narrow cytoplasm of luteal nonparenchymal cells is observed (arrows). F, A negative control of ovarian section, obtained 10 days after hCG injection and incubated with normal rabbit serum in place of primary antiserum, shows no immunofluorescent staining. G, Granulosa cell layer; T, theca cell layer; O, oocyte. Bar ϭ 50 m. greater molecular mass also was detected. This protein of approximately 150 kDa also has been identified in activated macrophages (25, 26, 32, 35) , in kidney from LPS-injected rats (27) , in human ovarian tumors (36) , and in COS-7 cells transfected with eNOS complementary DNA, where it was thought to represent a posttranscriptionally modified form of eNOS (30) .
The changes in relative amounts of iNOS in rat ovaries were quantitated using laser densitometry (Fig. 4B) . Expression of iNOS was low in ovaries from control rats and was not significantly increased during PMSG-induced follicular development. In contrast, hCG injection increased the level of ovarian iNOS by 6-fold relative to control rats (P Ͻ 0.05). As luteinization progressed (20 h after hCG injection) the iNOS band intensity was 7-fold higher than control ovaries (P Ͻ 0.05) but was not significantly higher than the previous treatment group. However, iNOS levels increased 10-fold above control by 10 days after hCG injection (P Ͻ 0.05). The lack of regulation of GAPDH levels during these ovarian stages supports the specificity of the iNOS response (Fig. 5) .
These quantitative data strengthen our immunostaining results and demonstrate that ovarian iNOS is significantly increased during hCG-induced ovulation in rats.
Discussion
Cells in the rat ovary synthesize NO, which has been postulated to play a number of roles in ovarian physiology (12, 13, 15) . The purpose of the present study was to examine the expression of NOS isoforms in the rat ovary and their possible regulation during follicular development, luteinization, and pseudopregnancy. We used the superovulated rat model because, by injecting immature rats with PMSG and hCG, we could obtain ovaries containing follicles at synchronized stages of development (17, 18) . Using immunohistochemistry and Western blot analysis, we demonstrated that eNOS and iNOS proteins, but not bNOS, are expressed in the rat ovary in a cell-specific manner and that their levels are regulated by gonadotropins.
FIG. 5. Representative
Western blot of GAPDH protein in rat ovaries during follicular development, ovulation, and pseudopregnancy. To verify equal protein loading, Immobilon-P membranes that were used for iNOS immunodetection were stripped of bound antibody and reprobed using a monoclonal GAPDH antibody. Lanes are as follows: 1 ϭ 0.4 g LPS-activated RAW 264.7 macrophages (LPS/RAW cells); 2 ϭ ovary from control rats (no PMSG, 27 days old); 3 ϭ ovary 48 h after PMSG injection (27-day-old rats); 4 ϭ ovary 12 h after hCG injection; 5 ϭ ovary 20 h after hCG injection; 6 ϭ ovary 10 days after hCG injection; 7 ϭ 16 g of bovine endothelial (End.) cells, 8 -13 ϭ negative controls to lanes 2-7, respectively, when GAPDH antibody was omitted. The positions of molecular mass markers are indicated.
FIG. 4. A, Representative
Western blot of iNOS protein in rat ovaries during follicular development, ovulation, and pseudopregnancy. Ovarian homogenates (65 g) were subjected to 4 -20% gradient SDS-PAGE, followed by immunoprobing with a monoclonal iNOS antibody. In (A), lanes are as follows: 1 ϭ 0.4 g LPS-activated RAW 264.7 macrophages (LPS/RAW cells); 2 ϭ ovary from control rats (no PMSG, 27 days old); 3 ϭ ovary 48 h after PMSG injection (27-day-old rats); 4 ϭ ovary 12 h after hCG injection; 5 ϭ ovary 20 h after hCG injection; 6 ϭ ovary 10 days after hCG injection; 7-8 ϭ negative controls to lanes 5 and 6, respectively, when iNOS antibody was omitted; 9 ϭ 16 g of bovine endothelial (End.) cells; 10 -11 ϭ 20 g of liver and spleen, respectively, from rat injected with LPS (LPS/liver and LPS/ spleen, respectively). The positions of molecular mass markers are indicated. B, Quantitative analysis of ovarian iNOS expression after gonadotropin treatment. The immunoblot signals were quantitated by a densitometer, and the value for no PMSG (control) was arbitrarily set as 1. Data points represent the mean Ϯ SEM; n ϭ 3 rats/ group. Means with different superscripts are significantly different (P Ͻ 0.05).
The various isoforms of NOS often are named after the cell in which the enzyme was first described (e.g. eNOS was first discovered in the endothelium); however, NOS isoforms have been described in a variety of cell types and in several species (2, 23, 37) . eNOS is a membrane-bound protein of 135 kDa that is synthesized by endothelial cells and other cell types in several bovine, human, porcine, and rodent tissues (adrenal gland, kidney, lung, ovary, pancreatic islets, placenta, uterus) (8, 12, 15, 16, 23, 24, 38 -40) . The immunohistochemical localization of eNOS in the present study indicates that this enzyme also is present in mural granulosa cells, theca cell layer and ovarian stroma of antral follicles, and luteal parenchymal and nonparenchymal cells of the CL in the rat ovary. The present results extend our previous studies that demonstrated eNOS expression by endothelial and steroidogenic cells of luteinized ovaries (13) . Our findings also are in agreement with other studies that have localized eNOS within the endothelium of the ovarian vasculature (12, 15) , theca interna of preovulatory follicles in rodents (12, 40) , and in human granulosa-luteal cells (8) .
In the present study, we have documented hormonal regulation of ovarian eNOS. The expression of eNOS increased after PMSG-induced follicular development and continued to rise after an ovulatory dose of hCG to reach its maximum expression in the CL. Our observations concerning hormonal regulation of eNOS protein support those of Van Voorhis et al. (15) , who observed an increase in eNOS mRNA after gonadotropin stimulation of immature rats. eNOS is commonly described as a constitutively expressed protein, but its levels can be altered by various stimuli, including shearstress, tumor necrosis factor-␣, and estrogen (35, 38, 41 ). Our results demonstrate that, in the ovary, eNOS protein levels are regulated by hormones during ovarian follicular development and luteinization.
iNOS (130 -135 kDa protein) was first isolated and characterized from activated murine macrophages (4, 42) . Increased expression of iNOS in other cell types has been correlated with a number of pathological situations such as septic shock, stroke, and diabetes (1, 37, 43, 44) . Studies of iNOS expression during normal physiology have been less frequent; however, exciting new evidence points to expression of iNOS in response to signals that are noninflammatory or nonimmunologic (45) (46) (47) . Reported examples of tissues normally expressing iNOS include the fallopian tubes, kidney, thymus, and uterus in the rat, mouse uterus, pregnant rabbit uterus, and large airways in humans (35, 44 -48) . In the present investigation, we have demonstrated that the rat ovary also expresses iNOS protein, which responds to gonadotropin stimulation of normal follicular development. Using immunocytochemistry, we localized iNOS in the theca cell layer and ovarian stroma of antral follicles and nonparenchymal cells of the CL. In contrast to results with eNOS, granulosa cells were devoid of staining. These results extend our previous studies that showed that iNOS is expressed in luteal cells located around the blood vessel network within the CL (13) . Our data concerning the location of iNOS protein differs from a previous report demonstrating expression of iNOS mRNA in granulosa cells of secondary preantral follicles (15) .
Our immunostaining results were confirmed by Western blot analysis, which indicated the presence of iNOS protein in the rat ovary. The levels of iNOS were regulated by gonadotropins, albeit in a different manner from that observed with eNOS. During PMSG-induced follicular development, iNOS protein levels remained relatively constant. An ovulatory dose of hCG resulted in an increase in iNOS protein that reached its maximum level in the late CL. Others have reported maximal expression of iNOS mRNA levels in unstimulated ovaries that were reduced after hCG injection (15) . Thus, hCG administration results in decreased iNOS mRNA, whereas iNOS protein levels continue to rise. These data suggest that hCG may facilitate the translation of iNOS mRNA into protein. A similar pattern of regulation of eNOS mRNA and protein by hypoxia has been reported in endothelial cells (41) . Several lines of evidence support multiple roles for NO within the ovary. NO has been shown to negatively influence estradiol synthesis in both rat and human luteal cells in vitro (8, 13) . NO has been implicated also in the gonadotropin regulation of an ovarian blood-follicle barrier, which has been shown to exist at the level of the ovarian microvasculature (12) . NO has been suggested to act as a potent and fast-acting signal that regulates the barrier's ability to block the entrance of certain blood components into the follicular fluid (12) . Our observations that eNOS and iNOS are expressed in theca cell layer and stroma cells of preovulatory follicles support this possible role for ovarian NO.
The ovarian NO/NOS system also has been suggested to function in ovulation and follicle rupture through its known effects on vascular dilation and ovulatory leukocyte distribution (10, 14, 49, 50) . It also has been demonstrated that pharmacological inhibitors of NOS suppress hCG-induced ovulation in rodents (10, 12) . The specificity of this effect was confirmed by the ability of a NO generator to reverse the inhibitory action (10) . We observe an induction of both eNOS and iNOS with an ovulatory dose of hCG, and thus our data certainly support a role for increased NO production during ovulation. NO also has been shown to reduce follicular apoptosis in ovaries (11) , which could explain a reduction in ovulation rate with NOS inhibitors (7, 9, 10, 12, 14) .
In summary, we have demonstrated that eNOS and iNOS are present in the rat ovary. During ovarian follicular development, they respond to gonadotropin stimulation with distinct cell-specific patterns of expression. The goal of future studies is to understand the unique function of each NOS isoform in ovarian physiology.
